Free tool
FAERS Monitor: Caverject
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020379 or its brand name (Caverject, Alprostadil). Reports on generic versions are filed under their own applications.
Reports
2,865
Serious
2,024
71% of reports
Hospitalization
642
Death reported
244
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective638
- off label use143
- erection increased104
- haemoglobin decreased83
- lymphocyte count decreased79
- pyrexia76
- diarrhoea72
- erectile dysfunction71
- penile pain70
- condition aggravated68
- pain65
- cardiac failure64
- blood glucose increased63
- injection site pain61
- blood urea increased59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 76 |
| 2005 | 91 |
| 2006 | 126 |
| 2007 | 85 |
| 2008 | 87 |
| 2009 | 47 |
| 2010 | 363 |
| 2011 | 185 |
| 2012 | 128 |
| 2013 | 82 |
| 2014 | 67 |
| 2015 | 127 |
| 2016 | 180 |
| 2017 | 206 |
| 2018 | 139 |
| 2019 | 184 |
| 2020 | 141 |
| 2021 | 118 |
| 2022 | 99 |
| 2023 | 91 |
| 2024 | 101 |
| 2025 | 74 |
| 2026 | 67 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,294 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| erection increasedSignal | 104 | 187.2 | 154.6 | 18,601 |
| penile painSignal | 70 | 172.8 | 136.7 | 11,514 |
| lymphocyte count decreasedSignal | 79 | 33.0 | 26.5 | 2,407 |
| blood urea increasedSignal | 59 | 26.0 | 20.2 | 1,388 |
| erectile dysfunctionSignal | 71 | 20.4 | 16.2 | 1,285 |
| haemoglobin decreasedSignal | 83 | 5.9 | 4.8 | 337 |
| cardiac failureSignal | 64 | 5.9 | 4.6 | 254 |
| drug ineffectiveSignal | 638 | 3.6 | 3.3 | 1,247 |
| blood glucose increasedSignal | 63 | 2.5 | 1.9 | 53 |
| condition aggravated | 68 | 1.6 | 1.3 | 17 |
| pyrexia | 76 | 1.6 | 1.3 | 17 |
| injection site pain | 61 | 1.5 | 1.1 | 9 |
| off label use | 143 | 1.2 | 1.0 | 5 |
| diarrhoea | 72 | 0.8 | 0.7 | 3 |
| pain | 65 | 0.8 | 0.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.